Search
  1. Home
  2. East Africa
  3. Uganda
  • News

US validates anti-AIDS drug study

    JOHANNESBURG

    The US Institute of Medicine (IOM) has approved a Ugandan study showing that the anti-AIDS drug, nevirapine, effectively prevents mother-to-child transmission (PMTCT) of HIV.

    Controversy surrounding the drug erupted in December 2004, after the Associated Press news agency claimed US health authorities had covered up information about nevirapine's negative effects, and alleged flaws in the Ugandan study.

    However, in a recent statement, IOM confirmed that the east African country had conducted the trial in accordance with US and international standards of research and patient care, and that there was no need to retract or discount the study's findings.

    The single-dose drug has become the standard of care for PMTCT in Uganda and much of Africa.

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join